AZ fails to prove Caprelsa's added benefit in Germany
This article was originally published in Scrip
Executive Summary
AstraZeneca's thyroid cancer drug Caprelsa (vandetanib) has no proven added benefit, according to Germany's Institute for Quality Effectiveness and Healthcare Systems (IQWiG).